quidelortho - QDEL
QDEL
Close Chg Chg %
27.82 -0.08 -0.27%
Open Market
27.75
-0.08 (0.27%)
Volume: 304.13K
Last Updated:
Dec 5, 2025, 2:55 PM EDT
Company Overview: quidelortho - QDEL
QDEL Key Data
| Open $28.09 | Day Range 27.51 - 28.30 |
| 52 Week Range 19.50 - 49.45 | Market Cap $1.89B |
| Shares Outstanding 67.93M | Public Float 67.24M |
| Beta 0.58 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$17.02 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.75M |
QDEL Performance
| 1 Week | 1.72% | ||
| 1 Month | 36.71% | ||
| 3 Months | -3.00% | ||
| 1 Year | -27.17% | ||
| 5 Years | -85.63% |
QDEL Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
8
Full Ratings ➔
About quidelortho - QDEL
QuidelOrtho Corp. operates as a vitro diagnostics company. It is focused on developing and manufacturing diagnostic products. The company was founded on May 27, 2022 and is headquartered in San Diego, CA.
QDEL At a Glance
QuidelOrtho Corp.
9975 Summers Ridge Road
San Diego, California 92121
| Phone | 1-800-552-1100 | Revenue | 2.79B | |
| Industry | Medical Specialties | Net Income | -2,052,000,000.00 | |
| Sector | Health Technology | Employees | 6,600 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
QDEL Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 1.068 |
| Price to Book Ratio | 0.998 |
| Price to Cash Flow Ratio | 35.83 |
| Enterprise Value to EBITDA | 11.069 |
| Enterprise Value to Sales | 1.995 |
| Total Debt to Enterprise Value | 0.483 |
QDEL Efficiency
| Revenue/Employee | 422,030.303 |
| Income Per Employee | -310,909.091 |
| Receivables Turnover | 6.172 |
| Total Asset Turnover | 0.359 |
QDEL Liquidity
| Current Ratio | 1.22 |
| Quick Ratio | 0.686 |
| Cash Ratio | 0.098 |
QDEL Profitability
| Gross Margin | 38.985 |
| Operating Margin | 1.745 |
| Pretax Margin | -76.524 |
| Net Margin | -73.67 |
| Return on Assets | -26.425 |
| Return on Equity | -51.362 |
| Return on Total Capital | -36.217 |
| Return on Invested Capital | -32.197 |
QDEL Capital Structure
| Total Debt to Total Equity | 89.844 |
| Total Debt to Total Capital | 47.325 |
| Total Debt to Total Assets | 38.483 |
| Long-Term Debt to Equity | 77.35 |
| Long-Term Debt to Total Capital | 40.744 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Quidelortho - QDEL
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 1.70B | 3.26B | 2.99B | 2.79B | |
Sales Growth
| +2.22% | +92.11% | -8.26% | -6.95% | |
Cost of Goods Sold (COGS) incl D&A
| 427.66M | 1.46B | 1.71B | 1.70B | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 54.38M | 283.60M | 457.20M | 453.40M | |
Depreciation
| 26.98M | 151.10M | 252.40M | 250.00M | |
Amortization of Intangibles
| 27.40M | 132.50M | 204.80M | 203.40M | |
COGS Growth
| +36.71% | +241.84% | +16.98% | -0.62% | |
Gross Income
| 1.27B | 1.80B | 1.28B | 1.09B | |
Gross Income Growth
| -5.78% | +41.73% | -28.75% | -15.39% | |
Gross Profit Margin
| +74.82% | +55.20% | +42.87% | +38.99% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 355.06M | 811.50M | 1.01B | 985.50M | |
Research & Development
| 95.70M | 190.50M | 246.80M | 218.70M | |
Other SG&A
| 259.36M | 621.00M | 763.20M | 766.80M | |
SGA Growth
| +25.27% | +128.56% | +24.46% | -2.43% | |
Other Operating Expense
| - | 12.30M | 27.10M | 51.80M | |
Unusual Expense
| 9.77M | 160.00M | 113.40M | 2.01B | |
EBIT after Unusual Expense
| 906.07M | 817.40M | 132.90M | (1.96B) | |
Non Operating Income/Expense
| (5.01M) | (7.50M) | (44.50M) | 43.60M | |
Non-Operating Interest Income
| - | - | - | 28.00M | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 700.00K | 74.00M | 117.50M | 217.00M | |
Interest Expense Growth
| -44.58% | +10,471.43% | +58.78% | +84.68% | |
Gross Interest Expense
| 700.00K | 74.00M | 117.50M | 217.00M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| 900.36M | 735.90M | (29.10M) | (2.13B) | |
Pretax Income Growth
| -13.45% | -18.27% | -103.95% | -7,224.74% | |
Pretax Margin
| +53.01% | +22.55% | -0.97% | -76.52% | |
Income Tax
| 196.13M | 187.20M | (19.00M) | (79.50M) | |
Income Tax - Current - Domestic
| 191.20M | 211.00M | (50.90M) | 3.80M | |
Income Tax - Current - Foreign
| 2.29M | 17.60M | 36.40M | 22.10M | |
Income Tax - Deferred - Domestic
| 4.63M | (41.20M) | 4.90M | (129.90M) | |
Income Tax - Deferred - Foreign
| (1.99M) | (200.00K) | (9.40M) | 24.50M | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| 704.23M | 548.70M | (10.10M) | (2.05B) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| 704.23M | 548.70M | (10.10M) | (2.05B) | |
Net Income Growth
| -13.09% | -22.08% | -101.84% | -20,216.83% | |
Net Margin Growth
| +41.46% | +16.82% | -0.34% | -73.67% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| 704.23M | 548.70M | (10.10M) | (2.05B) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| 704.23M | 548.70M | (10.10M) | (2.05B) | |
EPS (Basic)
| 16.7362 | 9.6602 | -0.1512 | -30.5357 | |
EPS (Basic) Growth
| -12.99% | -42.28% | -101.57% | -20,095.57% | |
Basic Shares Outstanding
| 42.08M | 56.80M | 66.80M | 67.20M | |
EPS (Diluted)
| 16.4255 | 9.5592 | -0.1512 | -30.5357 | |
EPS (Diluted) Growth
| -11.68% | -41.80% | -101.58% | -20,095.57% | |
Diluted Shares Outstanding
| 42.87M | 57.40M | 66.80M | 67.20M | |
EBITDA
| 970.22M | 1.26B | 703.50M | 502.00M | |
EBITDA Growth
| -12.95% | +29.97% | -44.21% | -28.64% | |
EBITDA Margin
| +57.12% | +38.64% | +23.50% | +18.02% |
Snapshot
| Average Recommendation | HOLD | Average Target Price | 37.714 | |
| Number of Ratings | 8 | Current Quarters Estimate | 0.423 | |
| FY Report Date | 12 / 2025 | Current Year's Estimate | 2.081 | |
| Last Quarter’s Earnings | 0.80 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 1.85 | Next Fiscal Year Estimate | 2.488 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 7 | 7 | 7 | 7 |
| Mean Estimate | 0.42 | 0.82 | 2.08 | 2.49 |
| High Estimates | 0.46 | 1.04 | 2.12 | 2.76 |
| Low Estimate | 0.39 | 0.70 | 2.06 | 2.20 |
| Coefficient of Variance | 5.39 | 13.80 | 1.13 | 8.62 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 2 | 2 | 4 |
| OVERWEIGHT | 1 | 1 | 1 |
| HOLD | 4 | 4 | 3 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 1 | 1 | 1 |
| MEAN | Hold | Hold | Overweight |
SEC Filings for Quidelortho - QDEL
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Quidelortho - QDEL
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Nov 26, 2025 | Kenneth J. Widder Director | 37,061 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $27.81 per share | 1,030,666.41 |
| Nov 26, 2025 | Kenneth J. Widder Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Nov 26, 2025 | Kenneth J. Widder Director | 41,087 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $15.74 per share | 646,709.38 |
| Nov 26, 2025 | Joseph Michael Busky Chief Financial Officer | 6,920 | Open market or private purchase of non-derivative security Non-derivative transaction at $26.06 per share | 180,335.20 |
| Nov 21, 2025 | Michelle A. Hodges Chief Legal Officer | 10,698 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Nov 21, 2025 | Brian J. Blaser President and CEO | 29,533 | Open market or private purchase of non-derivative security Non-derivative transaction at $21.34 per share | 630,234.22 |
| Nov 21, 2025 | Michelle A. Hodges Chief Legal Officer | 34,752 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Nov 21, 2025 | Michelle A. Hodges Chief Legal Officer | 32,035 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $21.28 per share | 681,704.80 |
| Sep 18, 2025 | Lee Bowman Chief Human Resources Officer | 1,647 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $28.92 per share | 47,631.24 |
| Sep 18, 2025 | Lee Bowman Chief Human Resources Officer | 5,132 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Sep 18, 2025 | Lee Bowman Chief Human Resources Officer | 2,565 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| May 21, 2025 | Ann D. Rhoads Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 21, 2025 | Ann D. Rhoads Director | 8,687 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| May 21, 2025 | Mary Lake Polan Director | 6,583 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| May 21, 2025 | Kenneth F. Buechler Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 21, 2025 | Kenneth F. Buechler Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 21, 2025 | Kenneth F. Buechler Director | 87,777 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| May 21, 2025 | Kenneth F. Buechler Director | 87,541 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| May 21, 2025 | Ann D. Rhoads Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 21, 2025 | Edward L. Michael Director | 16,257 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |